Fintel reports that on November 26, 2025, Chardan Capital maintained coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a Buy recommendation. Analyst Price Forecast Suggests 49.92% Upside As of ...
Hosted on MSN
Crispr Therapeutics AG Files $600M Share Offering
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Crispr Therapeutics AG ( (CRSP)) has ...
CRISPR Therapeutics CRSP is expected to report third-quarter 2025 earnings later this week. The Zacks Consensus Estimate for quarterly sales is pegged at $6.71 million, while that for earnings is ...
Discover the Center for Research in Security Prices (CRSP) at the Booth School of Business, including its historical data on ...
CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback